Kristiina Vuori, MD
Known title: DirectorCIK: 0001612627
Kristiina Vuori, MD's purchase track record
How the stock did after each of Kristiina Vuori, MD's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 29, 2024
Stock higher 6 months later
0%
3 months: 67%
Median 6-month return
-10.4%
3 months: +2.5%
Beat the S&P 500
0%
median -11.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/3/2024 | INBX | $100K | +2.5% | -10.4% | -5.3% |
| 9/10/2024 | INBX | $100K | -1.4% | -10.4% | +1.4% |
| 8/29/2024 | INBX | $100K | +9.7% | -9.4% | +4.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INBX | ▲ Buy | Open Market | 6,667 | $100K | 10/3/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 6,457 | $97K | 9/11/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 179 | $3K | 9/10/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 7,140 | $100K | 8/29/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.